Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats

• Published in: Pharmacology, biochemistry and behavior biochemistry and behavior, 2010-11, Vol.97 (1), p.92-100
• Main Authors: Tallett, A.J., Blundell, J.E., Rodgers, R.J.
• Format: Article
• Language: English
• Subjects: Acute effects; Animals; Appetite - drug effects; Appetite - physiology; Behavioural satiety sequence; Cyclobutanes - administration & dosage; Drug Administration Schedule; Drug Therapy, Combination; Feeding behaviour; Food intake; Low doses; Male; Monotherapy; Piperidines - administration & dosage; Polytherapy; Pyrazoles - administration & dosage; Rats; Reaction Time; Rimonabant; Satiety Response - drug effects; Satiety Response - physiology; Sibutramine; Weight Gain - drug effects; Weight Gain - physiology
• ISSN: 0091-3057; 1873-5177
• DOI: 10.1016/j.pbb.2009.12.010

In view of its potential advantages, drug polytherapy is currently attracting significant interest in the field of obesity research. In this context, concurrent manipulation of serotonergic and cannabinoid pathways in rodents has been found to reduce food and fluid intake in both an additive or synergistic manner. To further assess the value of this polytherapeutic approach, the current study examined the acute effects of low-dose combinations of the cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (0.5 mg/kg) and the dual serotonin- and noradrenaline-reuptake inhibitor sibutramine (0.125 and 0.25 mg/kg) in male rats. Ethological analysis was used to generate comprehensive behavioural profiles, including the behavioural satiety sequence (BSS). Findings confirmed that, although neither drug given alone significantly altered food intake, feeding behaviour or weight gain, rimonabant per se tended to reduce consumption and time spent feeding while significantly increasing scratching and grooming responses. However, none of these effects of the CB1 receptor antagonist/inverse agonist was significantly altered by the presence of either dose of sibutramine. In striking contrast to recent reports of acute low-dose interactions (enhanced appetite suppression and reduced side-effects) between rimonabant and naloxone, present results would not appear to support the clinical potential of rimonabant/sibutramine polytherapy for obesity.